Merck Singulair Allergy Switch Must Address Neuropsychiatric Concerns
This article was originally published in The Tan Sheet
Executive Summary
FDA will ask the Nonprescription Drug Advisory Committee May 2 to weigh the risks and benefits of switching Merck’s Singulair Allergy 10 mg montelukast sodium for allergy relief. Among the agency’s concerns about potential neuropsychiatric events and off-label use by children and asthmatics.
You may also be interested in...
Merck Singulair Switch NDA Limits Indication to Allergies, Omits Asthma
Merck will try to convince an FDA advisory committee May 2 to partially switch its blockbuster Rx drug Singulair to OTC for allergy relief in adults only. The firm will not seek to switch the Rx indications for asthma or allergy relief in children.
J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
Ensuring Leading Position For GSK Consumer Products Touted In Management Shift
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.